AffiliationDepartment of Medicine, Cork University Hospital, Cork, Ireland. email@example.com
Inflammatory Bowel Diseases/*immunology/*therapy
Interleukin-10/administration & dosage/*biosynthesis/genetics/immunology
Recombinant Proteins/administration & dosage/biosynthesis/immunology
MetadataShow full item record
CitationScience. 2000 Aug 25;289(5483):1311-2.
JournalScience (New York, N.Y.)
AbstractIn developed countries as many as two individuals in every thousand suffer from inflammatory bowel disease (ulcerative colitis and Crohn's disease). In his Perspective, Shanahan discusses a new therapeutic approach to treating these conditions in which bacteria normally found in the gut are engineered to produce the anti-inflammatory cytokine interleukin-10 and then are fed as probiotics to mice with these disorders (Steidler et al.).
- Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.
- Authors: Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E
- Issue date: 2000 Aug 25
- Engineered and wild-type L. lactis promote anti-inflammatory cytokine signalling in inflammatory bowel disease patient's mucosa.
- Authors: Simčič S, Berlec A, Stopinšek S, Štrukelj B, Orel R
- Issue date: 2019 Feb 27
- Structure of the intestinal flora responsible for development of the gut immune system in a rodent model.
- Authors: Umesaki Y, Setoyama H
- Issue date: 2000 Sep
- Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin.
- Authors: Huibregtse IL, Snoeck V, de Creus A, Braat H, De Jong EC, Van Deventer SJ, Rottiers P
- Issue date: 2007 Aug
- Delivery of therapeutic proteins through Lactococcus lactis.
- Authors: Neirynck S, Steidler L
- Issue date: 2006